Oruka Therapeutics, Inc.
ORKA
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.6B
$92.51
▲ +1.67%
P/E
-37.45
Mkt Cap
$5.6B
52-Wk Range
$14.67–$115.52
52-Week Range
$14.67 - $115.52
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 485.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary monoclonal antibody platform technology
- Focused pipeline targeting underserved I&I indications
- Clinical-stage candidates with differentiated mechanisms of action
Bear Case
1 risk
- Low volatility (beta -0.4).
Growth
Stable outlook
Clinical trial progression of ORKA-001 and ORKA-002
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+44.4% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ORKA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 10, 2026
Reported EPS of -$0.55 vs -$0.51 consensus (-7.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
8 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: UBS · Jul 1, 2026
vs Industry
How ORKA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related